NEW IMAGING TECHNOLOGIES FOR AUTOIMMUNE DISEASES

Release Date: February 11, 1999

RFA:  AI-99-004

P.T.

National Institute of Allergy and Infectious Diseases
National Cancer Institute
National Center for Research Resources
National Eye Institute
National Heart, Lung and Blood Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Research on Women's Health

Letter of Intent Receipt Date:  March 15, 1999
Application Receipt Date:  May 6, 1999

THIS RFA USES THE MODULAR GRANT APPLICATION AND AWARD PROCESS.  THIS RFA INCLUDES
DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE FOLLOWED
WHEN PREPARING AN APPLICATION IN RESPONSE TO THIS RFA.

PURPOSE

The National Institute of Allergy and Infectious Diseases (NIAID), the National
Cancer Institute (NCI), the National Center for Research Resources (NCRR), the
National Eye Institute (NEI), the National Heart, Lung and Blood Institute
(NHLBI), the National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS), the National Institute of Dental and Craniofacial Research
(NIDCR), the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), the National Institute of Mental Health (NIMH), the National Institute
of Neurological Disorders and Stroke (NINDS), and the Office of Research on
Women's Health (ORWH) invite applications for research project grants to develop
new methods for in vivo imaging of the immune system in small animal models of
human autoimmune diseases.  Support will be provided for the development of high-
resolution imaging technologies to visualize active processes of immune cells in
vivo, including instrumentation and computational improvements, and the design,
development, synthesis and testing of new contrast agents.  These projects will
require the coordinated effort of experts in imaging and immunology to develop
innovative approaches for imaging immune cell movement, behavior and functions
in vivo using animal models of human autoimmune diseases.  Of particular interest
are studies designed to specifically label and follow lymphocytes and other
immune effector cells at various activation states throughout an ongoing immune
response.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This Request for Applications (RFA), New
Imaging Technologies for Autoimmune Diseases, is related to the priority areas
of immunization and infectious diseases and diabetes and chronic disabling
conditions.  Potential applicants may obtain a copy of "Healthy People 2000"
(Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-
00473-1) through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-512-1800).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic for-profit and non-profit
organizations; public and private institutions, such as universities, colleges,
hospitals, laboratories, units of State and local governments; and eligible
agencies of the Federal government.  Foreign institutions are not eligible to
apply for this RFA.  Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.

MECHANISM OF SUPPORT

The mechanism of support will be the individual research project grant (R01). The
total requested project period for an application submitted in response to this
RFA may not exceed five years.  Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the applicant.  This RFA
is a one-time solicitation.  Future competing renewal applications will compete
with all investigator-initiated applications and will be reviewed according to
customary referral and review procedures.

Specific application instructions have been modified to reflect the "MODULAR
GRANT APPLICATION AND AWARD" process which has been adopted by the NIH (see the
NIH Guide, December 15, 1998).

For this RFA, funds must be requested in $25,000 direct cost modules. A feature
of the modular grant is that no escalation is provided for future years, and all
anticipated expenses for all years of the project must be included within the
number of modules being requested.  Only limited budget information is required
and any budget adjustments made by the Initial Review Group will be in modules
of $25,000.

More detailed information about modular grant applications, including a sample
budget narrative justification pages and a sample biographical sketch, is
available via the Internet at url: 
http://grants.nih.gov/grants/funding/modular/modular.htm

FUNDS AVAILABLE

The estimated total funds (direct and indirect) available for the first year of
support for all awards made under this RFA will be $3,500,000.  In Fiscal Year
1999, the participating Institutes and Centers (ICs) plan to fund approximately
5 awards.  Budget requests for the first and, in some cases, the second year of
the project period should include the one-time costs associated with the
acquisition of necessary equipment.  Applicants requesting in excess of $750,000
in total (direct and indirect) first-year costs must obtain approval from the Dr.
Vicki Seyfert at the address listed under INQUIRIES prior to submission.

The usual PHS policies governing grants administration and management will apply. 
Although this program is provided for in the financial plans of the cosponsors,
awards pursuant to this RFA are contingent upon the availability of funds for
this purpose and the receipt of a sufficient number of applications of high
scientific merit.  Funding beyond the first and subsequent years of the grant
will be contingent upon satisfactory progress during the preceding years and
availability of funds.

RESEARCH OBJECTIVES

Background

Considerable progress has been achieved in the identification of immune cells and
factors involved in immune responses and the underlying mechanisms of immune cell
function.  However, little is known about the behavior and function of immune
cells in vivo.  For example, the kinetics of immune effector function in normal
and autoimmune responses and the influence of the three-dimensional environment
of the immune system on lymphocyte and other immune cell functions are not well
understood.  Increased knowledge of these aspects of immune responses are
critical for understanding both protective and pathogenic aspects of immunity,
as in the case of autoimmune diseases.  Currently available techniques are
limited in that they rely largely on the use of in vitro tissue culture systems,
histological analyses of tissues from animals or humans, or analyses of cells or
factors from peripheral blood or excised tissues/organs from sacrificed animals.

Recent advances in in vivo imaging technologies have the potential to overcome
many of these limitations.  Currently, most biomedical imaging devices have been
optimized for use in humans and do not possess the spatial resolution necessary
to visualize individual cells in vivo.  However, new scaled-down instrumentation
and high power computers have recently allowed for high-resolution and signal
sensitivity in small animal model systems.

More importantly, recent advances in the design and synthesis of contrast agents
have provided the means to specifically label cells and monitor their functions. 
One example is the addition of radiolabels to organic compounds that bind
selectively to receptors found only on nerve cells in the brain.  This approach
has allowed researchers to map the distribution of nerve cells that use dopamine
and serotonin with positron emission tomography (PET) scans.

Another example of high-resolution imaging is magnetic resonance imaging (MRI)
aided by injection of engineered paramagnetic metal ions such as gadolinium
(III), i.e., gadolinium surrounded by bulky organic groups that prevent its
interaction with water.  One of these engineered molecules, that has proven to
work well in vivo, is gadolinium bound to an organic group via a sugar molecule
that is cleaved by beta-galactosidase.  Cells or tissues genetically engineered
to express beta-galactosidase can then be specifically labeled by encounter with
the engineered gadolinium injected into the animal.  Use of these reagents in
conjunction with high-resolution MRI allows for mapping of specific cells or
tissues in living mice.

The application of these new high-resolution imaging strategies in animal models
of immune system diseases will provide a powerful non-invasive means to visualize
ongoing normal and deleterious immune responses.  In the case of autoimmune
diseases, specific cells involved in the process of tissue destruction could be
identified and followed.  Analysis of each cell's activation state and effector
functions in vivo will provide new insights into the mechanisms underlying
autoimmune pathogenesis in any organ in vivo.  Other aspects of immunity that
could be addressed through the application of high-resolution imaging include: 
localization and trafficking of lymphocytes following antigen encounter;
development of immune cells; and activation, proliferation, and effector
functions of lymphocytes following antigen encounter or during graft rejection. 
The eventual adaptation of high-resolution imaging for use in humans holds
promise for non-invasive detection, diagnosis and monitoring of immunologic
diseases, and a new approach for evaluating the efficacy of vaccines and
therapeutic agents, both of which will have significant impact on clinical
practice.

Research Objectives and Scope

The purpose of this RFA is to support R01 projects to develop new high-resolution
imaging technologies for visualizing cells in the immune system and how they
function to generate normal or deleterious immune responses.  This objective will
require a coordinated effort among experts in imaging, contrast agent design and
synthesis, and immunology to design the reagents and instrumentation necessary
to identify, follow and evaluate the function of different immune cells in normal
and abnormal immune responses. Examples of relevant technology development areas
include, but are not limited to, the following:

o  Development of new and/or refinement of existing imaging instrumentation to
analyze immune cell movement and function in small animals

o  Development of informatics tools necessary for data storage, analysis,
visualization and manipulation

o  Development of new classes of imaging agents with many of the following
properties:

--The ability to specifically bind and label for different cell populations,
including specific T cells, B cells, dendritic cells, or other immune effector
cells in vivo;

--The ability to specifically bind different antigen receptors on B or T cells,
including adaptation of anti-idotypic antibodies or soluble MHC/peptide as
imaging agents;

--The ability to alter imaging properties in response to physiologic changes to
enable in vivo detection of cellular responses such as metabolism, activation or
proliferation;

--The ability to remain inert until encounter with a specific reporter protein
in distinct cell populations, i.e., beta-galactosidase inducible gadolinium (see
above);

--The ability to bind specific cellular receptors, such as cytokine or chemokine
receptors and;

--The ability to specifically bind to viral or bacterial proteins for detection
and localization of pathogenic organisms in vivo.

New imaging technologies with the above properties should be used to address
fundamental mechanisms of immune responses in animal models of human autoimmune
diseases.  Areas of investigation include, but are not limited to, the following:

o  Identification of immune cell types, i.e., B, T or NK cells, involved in an
immune response to self-antigen in any organ or tissue in vivo.

o  Evaluation of immune cell types and their activation states in vivo during the
process of tissue destruction.

o  Assessment of antigen specific immune cell migration in vivo in response to
antigen.  Studies should be designed to evaluate the effect of antigen route of
entry on immune cell trafficking.

o  Assessment of the effects on immune cell migration, localization, and function
in genetically altered animal models.

o  Identification and migration of immune cells in vivo in response to
transplanted organs, cells and tissues, including the determination of cell types
involved in the acute rejection process and where they are localized.

o  Location of memory B and T cells when quiescent and following reactivation.

The areas outlined above are not intended to be all-inclusive.

SPECIAL REQUIREMENTS

Grantees will be invited to attend an annual meeting to be held at the NIH.  This
meeting will serve to bring together all investigators funded by this RFA to
discuss the progress of their projects and to identify gaps and opportunities in
imaging technologies as it applies to study of the immune system.  This meeting
will also serve to promote exchange of information and ideas between scientists
and to make recommendations to assist NIH Program Staff in planning future
initiatives in this area.  Budget requests should include travel expenses to
attend these annual meetings.

INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of the NIH that women and members of minority groups and their
sub-populations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear, compelling rationale,
and justification are provided that inclusion is inappropriate with respect to
the health of the subjects or the purpose of the research.  This policy results
from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43).

All investigators proposing research involving human subjects should read the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research", published in the Federal Register of March 28, 1994 (FR 59 14508-
14513) and the NIH Guide for Grants and Contracts, Vol. 23, No. 11, March 18,
1994 which is available via the WWW. at:
http://grants.nih.gov/grants/guide/notice-files/not94-100.html

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them.  This
policy applies to all initial (Type 1) applications  submitted for receipt dates
after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for Grants
and Contracts, March 6, 1998, and which is available at the following URL
address:  http://grants.nih.gov/grants/guide/notice-files/not98-024.html

Investigators may obtain copies from these sources or from the program contacts
listed under INQUIRIES who may also provide additional relevant information
concerning the policy.

LETTER OF INTENT

Prospective applicants are asked to submit, by March 15, 1999, a letter of intent
that includes a descriptive title of the overall proposed research; the name,
address and telephone number of the Principal Investigator; and the number and
title of this RFA.  Although the letter of intent is not required, is not
binding, does not commit the sender to submit an application, and does not enter
into the review of subsequent applications, the information that it contains
allows NIAID staff to estimate the potential review workload and to avoid
conflict of interest in the review.  The letter of intent is to be sent to Dr.
Madelon Halula at the address listed under INQUIRIES.

APPLICATION PROCEDURES

Applicants are strongly encouraged to contact the program contacts listed under
INQUIRIES with any questions regarding the responsiveness of their proposed
project to the goals of this RFA.

The research grant application form PHS 398 (rev. 4/98) is to be used in applying
for these grants.  Application kits are available at most institutional offices
of sponsored research and from the Division of Extramural Outreach and
Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC
7910, Bethesda, MD 20892-7910, telephone (301) 435-0714, email:
GrantsInfo@nih.gov.  Applications are also available on the World Wide Web at: 
http://grants.nih.gov/grants/forms.htm.

BUDGET INSTRUCTIONS

o  FACE PAGE:  Items 7a and 7b should be completed, indicating Direct Costs (in
$25,000 increments) and Total Costs [Modular Total Direct plus Facilities and
Administrative (F&A) costs] for the initial budget period.  Items 8a and 8b
should be completed indicating the Direct and Total Costs for the entire proposed
period of support.

o  DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4
of the PHS 398.  It is not required and will not be accepted with the
application.

o  BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the
categorical budget table on Form Page 5 of the PHS 398.  It is not required and
will not be accepted with the application.

o  NARRATIVE BUDGET JUSTIFICATION - Use a Modular Grant Budget Narrative page.
(See http://grants.nih.gov/grants/funding/modular/modular.htm for sample pages.) 
At the top of the page, enter the total direct costs requested for each year.

o  Under Personnel, list key project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should be
provided.

For Consortium/Contractual costs, provide an estimate of total costs (direct plus
facilities and administrative) for each year, each rounded to the nearest $1,000. 
List the individuals/organizations with whom consortium or contractual
arrangements have been made, the percent effort of key personnel, and the role
on the project.  The total cost for a consortium/contractual arrangement is
included in the overall requested modular direct cost amount.

Provide an additional narrative budget justification for any variation in the
number of modules requested.

o  BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by
reviewers in the assessment of each individual's qualifications for a specific
role in the proposed project, as well as to evaluate the overall qualifications
of the research team.  A biographical sketch is required for all key personnel,
following the instructions below.  No more than three pages may be used for each
person.  A sample biographical sketch may be viewed at:
http://grants.nih.gov/grants/funding/modular/modular.htm

- Complete the educational block at the top of the form page;
- List current position(s) and then previous positions;
- List selected peer-reviewed publications, with full citations;
- Provide information, including overall goals and responsibilities, on research
projects ongoing or completed during the last three years.

o  OTHER SUPPORT - Form Page 7.  This form must be completed for applications in
response to this RFA to allow awards to be negotiated and made on or before
September 30, 1999.

o  CHECKLIST - This page should be completed and submitted with the application. 
If the F&A rate agreement has been established, indicate the type of agreement
and the date. It is important to identify all exclusions that were used in the
calculation of the F&A costs for the initial budget period and all future budget
years.

The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information is
necessary following the initial review.

Applications not conforming to these guidelines will be considered unresponsive
to this RFA and will be returned without further review.

The RFA label available in the application form PHS 398 must be affixed to the
bottom of the face page.  Failure to use this label could result in delayed
processing of the application such that it may not reach the review committee in
time for review.  In addition, the RFA title and number must be typed on line 2
of the face page of the application form and the YES box must be marked.

Submit a signed, typewritten original of the application, including the
checklist, and three signed, exact, single-sided photocopies, in one package to:

CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)

At the time of submission, two additional exact copies of the application and all
five sets of any appendix material must be sent to Dr. Madelon Halula at the
address listed under INQUIRIES.  These copies must be sent at the same time as
the original and three copies are sent to the Center for Scientific Review (CSR),
failure to do so will prevent the application from being peer reviewed in time
for award in fiscal year 1999.

Applications must be received by May 6, 1999.  If an application is received
after that date, it will be returned to the applicant without review.  The CSR
will not accept any application in response to this RFA that is essentially the
same as one currently pending initial review, unless the applicant withdraws the
pending application.  The CSR will not accept any application that is essentially
the same as one already reviewed.  This does not preclude the submission of
substantial revisions of applications already reviewed, but such applications
must include an introduction addressing the previous critique.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness and adherence to the
Special Instructions above by CSR and for responsiveness by NIAID staff. 
Incomplete and/or non-responsive applications will be returned to the applicant
without further consideration.  Applications that are complete and responsive to
the RFA will be evaluated for scientific and technical merit by an appropriate
peer review group convened by the NIAID in accordance with the review criteria
stated below.  As part of the initial merit review, a process will be used by the
initial review group in which applications receive a written critique and undergo
a process in which only those applications deemed to have the highest scientific
merit, generally the top half of the applications under review, will be
discussed, assigned a priority score, and receive a second level review by the
National Advisory Allergy and Infectious Diseases Council.

Review Criteria

The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.  The
reviewers will comment on the following aspects of the application in their
written critiques in order to judge the likelihood that the proposed research
will have a substantial impact on the pursuit of these goals.  Each of these
criteria will be addressed and considered by the reviewers in assigning the
overall score weighting them as appropriate for each application.  Note that the
application does not need to be strong in all categories to be judged likely to
have a major scientific impact and thus deserve a high priority score.  For
example, an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.

1.  Significance.  Does this study address an important problem? If the aims of
the application are achieved, how will scientific knowledge be advanced?  What
will be the effect of these studies on the concepts or methods that drive this
field?

2.  Approach.  Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project?  Does the applicant acknowledge potential problem areas and consider
alternative tactics?

3.  Innovation.  Does the project employ novel concepts, approaches or method? 
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?

4.  Investigator.  Is the investigator appropriately trained and well suited to
carry out this work?  Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?

5.  Environment.  Does the scientific environment in which the work will be done
contribute to the probability of success?  Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements?  Is there evidence of institutional support?

The initial review group will also examine: the appropriateness of proposed
project budget and duration; the adequacy of plans to include both genders,
minorities and their subgroups, and children as appropriate for the scientific
goals of the research and plans for the recruitment and retention of subjects;
the provisions for the protection of human and animal subjects; and the safety
of the research environment.

Schedule

Letter of Intent Receipt Date:  March 15, 1999
Application Receipt Date:       May 6, 1999
Scientific Review Date:         July 1999
Advisory Council Date:          September 1999
Earliest Award Date:            September 30, 1999

AWARD CRITERIA

Funding decisions will be made on the basis of scientific and technical merit as
determined by peer review, program balance, and the availability of funds.  The
earliest anticipated date of award is September 30, 1999.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.  The
opportunity to clarify any issues or questions from potential applicants is
welcome.

Direct inquiries regarding programmatic issues to:

Dr. Vicki Seyfert
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4A21
Bethesda, MD  20892
Telephone:  (301) 496-7551
FAX:  (301) 402-2571
Email:  vs62y@nih.gov

Barbara Y. Croft, Ph.D.
Diagnostic Imaging Program
National Cancer Institute
6130 Executive Boulevard, Room 800
Rockville, MD 20892-7440
Bethesda, MD  20852 (for express/courier service)
Telephone:  (301) 496-9531
FAX:  (301) 480-5785
Email: bc129b@nih.gov

Louise E. Ramm, Ph.D.
Biomedical Technology
National Center for Research Resources
6705 Rockledge Drive, Room 5158
Bethesda, MD  20892
Telephone:  (301) 435-0879
Email:  louiseR@ep.ncrr.nih.gov

Dr. Ellen S. Liberman
Lens and Cataract and Glaucoma Programs
National Eye Institute
6120 Executive Boulevard, Suite 350, MSC 7164
Bethesda MD  20892-7164
Telephone:  (301) 496-0484
FAX:  (301) 402-0528
Email:  ellenliberman@nei.nih.gov

Alan S. Berson, Ph.D.
Division of Heart and Vascular Diseases
National Heart, Lung and Blood Institute
6701 Rockledge Drive, MSC 7940
Bethesda, MD  20892-7940
Telephone:  (301) 435-0513
FAX:  (301) 480-1454
Email:  BersonA@gwgate.nhlbi.nih.gov

Susana Serrate-Sztein, MD
Rheumatic Diseases Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
45 Center Drive, Room 5AS-25E, MSC 6500
Bethesda, MD  20892-6500
Telephone:  (301) 594-5032
FAX:  (301) 480-4543
Email:  sztein@exhange.nih.gov

Kenneth A. Gruber, Ph.D.
Division of Extramural Research
National Institute of Dental and Craniofacial Research
Building 45, Room 4AN-18C
Bethesda, MD  20892
Telephone:  (301) 594-4836
FAX:  (301) 480-8318
Email:  kenneth_gruber@nih.gov

Joan T. Harmon, Ph.D.
Division of Diabetes, Endocrinology and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Building 45, Room 5AN-18G
Bethesda, MD  20892
Telephone:  (301) 594-8813
FAX:  (301) 480-3503
Email:  Joan_Harmon@NIH.GOV

Dianne Rausch, Ph.D.
Office of AIDS Research
National Institute of Mental Health
6001 Executive Boulevard, Room 6209, MSC 9619
Bethesda, MD  20892-9619
Telephone:  (301) 443-6100
Email:  drausch@mail.nih.gov

Direct inquiries regarding review issues and special instructions for application
preparation; address the letter of intent to; and mail two copies of the
application and all five sets of appendices to:

Madelon Halula, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4C16
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 402-2636
FAX:  (301) 402-2638
Email:  mh30x@nih.gov

Direct inquiries regarding fiscal matters to:

Pamela G. Fleming
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4C25
Bethesda, MD 20892-7610
Rockville, MD 20852 (for express/courier service)
Telephone:  (301) 402-6580
FAX:  (301) 480-3780
Email:  pf49e@nih.gov

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance Nos.
93.856, 93.394, and 93.855.  Awards are made under authorization of the Public
Health Service Act, Sec. 301 (c), Public Law 78-410, as amended.  Awards will be
administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and
45 CFR Part 74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems review.

The Public Health Service strongly encourages all grant and contract recipients
to provide a smoke-free workplace and promote the non-use of all tobacco
products.  In addition, Public Law 103-227, the Pro-Children Act of 1994,
prohibits smoking in certain facilities (or, in some cases, any portion of a
facility) in which regular or routine education, library, day care, health care
or early childhood development services are provided to children.  This is
consistent with the PHS mission to protect and advance the physical and mental
health of the American people.


Return to Volume Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.